Principia biopharma inc. (PRNB)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Operating activities:
Net loss

-32,499

-24,924

-22,296

7,115

-13,687

9,377

6,683

1,797

310

Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of convertible preferred stock warrant liability

-

-

-

-

-

0

68

187

322

Amortization of discount on marketable securities

347

338

263

436

526

322

65

0

0

Depreciation

502

495

502

489

346

76

69

61

46

Stock-based compensation

4,389

3,249

3,252

3,476

2,205

1,377

686

372

366

Deferred rent

0

-272

-273

-252

472

277

468

0

0

Non-cash lease expense

131

-

-

-

0

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

462

2,507

-499

-1,137

-471

1,489

-8,875

10,093

-520

Deferred revenue

0

0

0

0

-5,160

-16,137

-13,564

-2,987

-11,449

Accounts payable

-227

-473

-1,557

-17

-35

-310

1,504

821

-981

Accrued liabilities

1,461

3,091

1,753

2,410

-492

1,375

1,600

-854

-159

Lease liability

-420

-

-

-

0

-

-

-

-

Net cash used in operating activities

-27,472

-21,679

-18,383

13,922

-16,406

-5,776

6,324

-10,696

-11,025

Investing activities:
Purchases of property and equipment

178

17

241

537

1,376

612

87

215

153

Maturities of marketable securities

84,761

47,356

49,025

69,125

34,410

5,000

8,500

0

0

Purchases of marketable securities

37,745

243,581

43,137

57,114

36,536

111,615

39,199

8,485

0

Net cash provided by (used in) investing activities

46,838

-196,242

5,647

11,474

-3,502

-107,227

-30,786

-8,700

-153

Financing activities:
Net proceeds from equity offerings

-

-

-

-

-

-

-

-

126

Proceeds from issuances of common stock upon exercise of options and participation in employee stock purchase plan

524

1,573

1,074

1,007

7

-

-

-

-

Net cash provided by financing activities

524

228,047

1,074

1,007

7

-1,561

163,576

-200

126

Net increase (decrease) in cash, cash equivalents and restricted cash

19,890

10,126

-11,662

26,403

-19,901

-114,564

139,114

-19,596

-11,052

Supplemental disclosures of cash flow information
Non cash tenant improvement allowance used for leasehold improvements

0

0

0

0

8,324

-8,324

8,324

0

0

Purchases of property and equipment accrued but not yet paid

0

0

-172

-121

293

578

49

-129

144